The Life Sciences Virtual Investor Forum, co-hosted by B2i Digital, Inc. and Zacks Small-Cap Research, will take place on June 24 and 25, 2026, featuring presentations from over 20 publicly traded life sciences companies. The event, held in partnership with Virtual Investor Conferences, offers investors live access to management teams across biotechnology, diagnostics, medical devices, and digital health. According to the press release, B2i Digital serves as the Official Marketing Partner, leveraging its distribution network of more than 1.7 million market participants to amplify the event. The company has supported over 115 investor conferences through its marketing engine.
Zacks Small-Cap Research, a preferred provider in the OTC Markets Group's Research Marketplace, will co-host the forum and provide independent company-sponsored research. The two-day lineup includes companies such as Protalix BioTherapeutics, CytoSorbents, Jaguar Health, Reviva Pharmaceuticals, 4DMedical, Prostatype Genomics, Abingdon Health, Innovotech, Lakewood-Amedex, Nasus Pharma, Kelyniam Global, IMUNON, Promino Nutritional Sciences, Envoy Medical, Coiled Therapeutics, Aspire Biopharma, Rocket Doctor AI, Phio Pharmaceuticals, aTyr Pharma, and NuFarm Ltd. Each company will have 30 minutes for a live presentation followed by a real-time Q&A session.
Investors can request one-on-one meetings with management teams through the Virtual Investor Conferences platform. Replays of presentations will be available on B2i Digital and OTC Markets YouTube channels. David Shapiro, CEO of B2i Digital, emphasized the importance of efficient access to management, stating that pairing that access with independent research from Zacks enhances the forum's value. The event aims to help investors evaluate companies across multiple sectors within life sciences.
For more details and registration, visit the Virtual Investor Conferences website. The forum highlights the growing trend of virtual events that provide direct investor engagement without geographical constraints. B2i Digital's role as marketing partner underscores the importance of digital distribution in reaching qualified investors. The event is particularly significant as it occurs amid a period of innovation in life sciences, with companies presenting advances in rare-disease therapies, oncology, molecular diagnostics, and AI-driven health solutions.
